Human genome and diseases: Review - Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin?

Cellular and Molecular Life Sciences

Volumn 60, Issue 9, 2003, Pages 1923-1932

  Poetsch, M ^a   Dittberner, T ^a   Woenckhaus, C ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Molecular genetic aberrations; RGP; Sporadic malignant melanoma; VGP

Indexed keywords

CANCER GROWTH; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 1P; CHROMOSOME 6Q; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; DISEASE ACTIVITY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC STABILITY; GENETIC VARIABILITY; GENOMICS; HISTOLOGY; HUMAN; HUMAN GENOME; MELANOMA; METASTASIS; MOLECULAR CLONING; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEQUENCE ANALYSIS; SKIN CANCER; SUPERFICIAL CANCER; TUMOR SUPPRESSOR GENE;

EID: 0141526329     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-2324-4     Document Type: Review

References (132)

1. Bevona C. and Sober A. J. (2002) Melanoma incidence trends. Dermatol. Clin. 20: 589-595
2. Heim S. and Mitelman F. (1995). Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. Wiley-Liss, New York
3. Barnhill R. L., Fine J. A., Roush G. C. and Berwick M. (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78: 427-432
4. Elder D. and Murphy G. F. (1991) Atlas of Tumor Pathology: Melanocytic Tumors of the skin. Armed Forces Institute of Pathology, Washington DC p. 146-149
5. Garbe C., Buttner P., Ellwanger U., Brocker E. B., Jung E. G., Orfanos C. E. et al. (1995) The Malignant Melanoma Central Register of the German Society of Dermatology 1983-1993. Epidemiologic developments and current therapeutic management of malignant melanoma of the skin. Hautarzt 46: 683-692
6. Ackerman A. B. (1993) A critique of an N.I.H. Consensus Development Conference about 'early' melanoma. Am. J. Dermatopathol. 15: 52-58
7. Clark W. H. Jr (1967) A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Advances in the Biology of the Skin, vol. VIII, pp. 621-647, Montagna W. (ed), Pergamon Press, New York
8. Clark W. H. Jr., From L., Bernardino E. A. and Mihm M. C. (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29: 705-727
9. Elder D. E., Guerry D. IV, Epstein M. N., Greene M. H. and Van Horn M. (1986) The biologic forms of malignant melanoma. Hum. Pathol. 17: 443-450
10. Meier F., Satyamoorthy K., Nesbit M., Hsu M. Y., Schittek B., Garbe C. et al. (1998) Molecular events in melanoma development and progression. Front Biosci. 3: D1005-1010
11. Thompson F. H., Emerson J., Olson S., Weinstein R., Leavitt S. A., Leong S. P. L. et al. (1995) Cytogenetics of 158 patients with regional or disseminated melanoma. Cancer Genet. Cytogenet. 83: 93-104
12. Mertens F., Johansson B., Hoglund M. and Mitelman F. (1997) Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 57: 2765-2780
13. Rao U. N. M., Jones M. W. and Finkelstein S. D. (2003) Genotypic analysis of primary and metastatic cutaneous melanoma. Cancer Genet. Cytogenet. 140: 37-44
14. Dracopoli N. C., Harnett P., Bale S. J., Stanger B. Z., Tucker M. A., Housman D. E. et al. (1989) Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc. Natl. Acad. Sci. USA 86: 4614-4618
15. Walker G. J., Palmer J. M., Walters M. K. and Hayward N. K. (1995) A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosom. Cancer 12: 134-141
16. de Wit P. E. J., Hopman A. H. N., van Muijen G. N. P., Smeets D. F. C. M., Beck J. L. M., Moesker O. et al. (1992) In situ detection of supernumerary aberrations of chromosome-specific repetitive DNA targets in interphase nuclei in human melanoma cell lines and tissue sections. J. Invest. Dermatol. 98: 450-458
17. Matsuta M., Imamura Y., Matsuta M., Kon S. and Sasaki K. (1994) Applications of DNA flow cytometry and fluorescence in situ hybridization using a chromosome-specific DNA probe on paraffin-embedded tissue sections of primary malignant melanomas. J. Dermatol. 21: 14-19
18. Matsuta M., Matsuta M., Kon S., Thompson C., LeBoit P. E., Weier H.-U. et al. (1994) Interphase cytogenetic of melanocytic neoplasm: numerical aberrations of chromosomes can be detected in interphase nuclei using centromeric DNA probes. J. Cutan. Pathol. 21: 1-6
19. Matsuta M., Imamura Y., Matsuta M., Sasaki K. and Kon S. (1997) Detection of numerical chromosomal aberrations in malignant melanomas using fluorescence in situ hybridization. J. Cutan. Pathol. 24: 201-205
20. Barks J. H., Thompson F. H., Taetle R., Yang J. M., Stone J. F., Wymer J. A. et al. (1997) Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromos. Cancer 19: 278-285
21. Wolfe K. Q., Southern S. A. and Herrington C. S. (1997) Interphase cytogenetic demonstration of chromosome 9 loss in thick melanomas. J. Cutan. Pathol. 24: 398-402
22. Bastian B. C., LeBoit P. E., Hamm H., Bröcker E. B. and Pinkel D. (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 56: 589-593
23. Bar-Eli M. (1997) Molecular mechanisms of melanoma metastasis. J. Cell. Physiol. 173: 275-278
24. Morita R., Fujimoto A., Hatta N., Takehara K. and Takata M. (1998) Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J. Invest. Dermatol. 111: 919-924
25. Balazs M., Adam Z., Treszl A., Begany A., Humyadi J. and Adany R. (2001) Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46: 222-232
26. Wiltshire R. N., Duray P., Bittner M. L., Visakorpi T., Meltzer P. S., Tuthill R. J. et al. (1995) Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res. 55: 3954-3957
27. Poetsch M., Woenckhaus C., Dittberner T., Pambor M., Lorenz G. and Herrmann F. H. (1998) Increased frequency of numerical chromosomal abnormalities and 1p36 deletions in isolated cells of paraffin sections of malignant melanoma detected by interphase cytogenetics. Cancer Genet. Cytogenet. 104: 146-152
28. Poetsch M., Woenckhaus C., Dittberner T., Pambor M., Lorenz G. and Herrmann F. H. (1998) Differences in chromosomal aberrations between nodular and superficial spreading malignant melanoma detected by interphase cytogenetics. Lab. Invest. 78: 883-888
29. Innominato P. F., Libbrecht L. and van den Oord J. J. (2001) Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J. Pathol. 194: 95-100
30. Sturm R. A., Satayamoorthy K., Meier F., Gardiner B. B., Smit D. J. and Vaidya Herlyn M. (2002) Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res. 62: 226-232
31. Böni R., Matt D., Voetmeyer A., Burg G. and Zhuang Z. (1998) Chromosomal allele loss in primary cutaneous melanoma is heterogeneous and correlates with proliferation. J. Invest. Dermatol. 110: 215-217
32. Herbst R. A., Mommert S., Schubach J., Podewski E. K., Kapp A. and Weiss J. (1999) Allelic loss at the p73 locus (1p36.33) is infrequent in malignant melanoma. Arch. Dermatol. Res. 291: 362-364
33. Poetsch M., Woenckhaus C., Dittberner T., Pambor M., Lorenz G. and Herrmann F. H. (1999) Significance of the small subtelomeric area of chromosome 1 (1p36.3) in the progression of malignant melanoma: FISH deletion screening with YAC DNA probes. Virch. Archiv 435: 105-111
34. Poetsch M, Dittberner T. and Woenckhaus C. (2003) Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res. 13: 29-33
35. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819
36. Kroiss M. M., Bosserhoff A. K., Vogt T., Buettner R., Bogenrieder T., Landthaler M. et al. (1998) Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res. 8: 504-509
37. Schittek B., Sauer B. and Garbe C. (1999) Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines. Int. J. Cancer 82: 583-586
38. Tsao H., Zhang X., Majewski P. and Haluska F. G. (1999) Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res. 59: 172-174
39. Codegoni A. M., Bertoni F., Patregnani C., Marinetti E., D'Incalci M. and Broggini M. (1999) Allelic expression of p73 in human ovarian cancers. Ann. Oncol. 10: 949-953
40. Tsujimoto T., Mochizuchi S., Iwadate Y., Namba H., Nagai M., Kawamoto T. et al. (2000) The p73 gene is not mutated in oligodendrogliomas, which frequently have a deleted region at chromosome 1p36.3. Anticancer Res. 20: 2495-2497
41. Ichimiya S., Nimura Y., Kageyama H., Takada N., Sunahara M., Shishikura T. et al. (2001) Genetic analysis of p73 localized at chromosome 1p36.3 in primary neuroblastomas. Med. Pediatr. Oncol. 36: 42-44
42. Xiang J., Lahti J. M., Grenet J., Easton J. and Kidd V. J. (1994) Molecular clotting and expression of alternatively spliced PITSLRE protein kinase isoforms. J. Biol. Chem. 269: 15786-15794
43. Xiang J., Lahti J. M. and Kidd V. J. (1994) 2-Aminopurine overrides a late telophase delay created by ectopic expression of the PITSLRE beta 1 protein kinase. Biochem Biophys. Res. Commun. 199: 1167-1173
44. Lahti J. M., Valentine M., Xiang J., Jones B., Amann J., Grenet J. et al. (1994) Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat. Genet. 7: 370-375
45. Dave B. J., Picketing D. L., Hess M. M., Weisenburger D. D., Armitage J. O. and Sanger W. G. (1999) Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non-Hodgkin's lymphoma. Cancer Genet. Cytogenet. 108: 120-126
46. cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer Genet. Cytogenet. 108: 91-99
47. Poetsch M., Dittberner T. and Woenckhaus C. (2001) Does the PITSLRE gene complex contribute to the pathogenesis of malignant melanoma of the skin? A study with patient-derived tumor samples. Cancer Genet. Cytogenet. 128: 181-182
48. Feng Y., Shi J., Goldstein A. M., Tucker M. A. and Nelson M. A. (2002) Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1p36 in melanoma cell lines and melanoma families. Int. J. Cancer 99: 834-838
49. Liu L., Shao G., Steele-Perkins G. and Huang S. (1997). The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter. J. Biol. Chem. 272: 2984-2991
50. He L., Yu J. X., Liu L., Buyse I. M., Wang M. S., Yang Q. C. et al. (1998). RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 58: 4238-4244
51. Jiang G.-L., Liu L., Buyse I. M., Simon D. and Huang S. (1999). Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int. J. Cancer 83: 541-547
52. Jiang G.-L. and Huang S. (2000). The yin-yang of PR-domain family genes in tumorigenesis. Histol. Histopathol. 15: 109-117
53. Chadwick R. B., Jiang G.-L., Bennington G. A., Yuan B., Johnson C. K., Stevens M. W. et al. (2000). Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA 97: 2662-2667
54. Piao Z., Fang W., Malkhosyan S., Kim H., Horii A., Perucho M. et al. (2000). Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability. Cancer Res. 60: 4701-4704
55. Sakurada K., Furukawa T., Kato Y., Kayama T., Huang S. and Horii A. (2001) RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable in cancers of the pancreas, stomach, and colorectum. Genes Chromosom. Cancer 30: 207-211
56. Jiang G.-L. and Huang S. (2001). Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers. Cancer Res. 61: 1796-1798
57. Poetsch M., Dittberner T. and Woenckhaus C. (2002) Frameshift mutations of RIZ, but no point mutations, in RIZ1 exons in malignant melanoma with deletions in 1p36. Oncogene 21: 3038-3042
58. Richetta A., Ottini L., Silipo V., Frati L., Carna A., Mariani-Costantini R. et al. (1997) Microsatellite instability in primary and metastatic melanoma. J. Invest. Dermatol. 109: 119-120
59. Richetta A., Ottini L., Falchetti M., Innocenzi D., Bottoni U., Faiola R. et al. (2001) Instability at sequence repeats in melanocytic tumours. Melanoma Res. 11: 283-289
60. Trent J. M., Thompson F. H. and Meyskens F. L. Jr (1989) Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. Cancer Res. 49: 420-423
61. Walker G. J., Palmer J. M., Walters M. K., Nancarrow D. J., Parsons P. G. and Hayward N. K. (1994) Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int. J. Cancer 58: 203-206
62. Trent J. M., Stanbridge E. J., McBride H. L., Meese E. U., Casey G., Arauho D. E. et al. (1990) Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247: 568-571
63. Welch D. R., Chen P., Miele M. E., McGray C. T., Bower J. M., Weissman, B. E. et al. (1994) Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 9: 255-262
64. Church S. L., Grant J. W., Ridnour L. A., Oberley L. W., Swanson P. E., Meltzer P. S. et al. (1993) Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA 90: 3113-3117
65. Miele M. E., McGary C. T. and Welch D. R. (1995) SOD2 (MnSOD) does not suppress tumorigenicity or metastasis of human melanoma C8161 cells. Anticancer Res. 15: 2065-2070
66. Miele M. E., Jewett M. D., Goldberg S. F., Hyatt D. L., Morelli C., Gualandi F. et al. (2000) A human melanoma metastasis suppressor locus maps to 6q16.3-q23. Int. J. Cancer 86: 524-528
67. Shirasaki F., Takata M., Hatta N. and Takehara K. (2001) Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res. 61: 7422-7425
68. Hildebrandt T., van Dijk M. C. R. F., van Muijen G. N. P. and Weidle U. H. (2001) Loss of heterozygosity of gene THW is frequently found in melanoma metastases. Anticancer Res. 21: 1071-1080
69. Nathrath M. H., Kuosaite V., Rosemann M., Kremer M., Poremba C., Wakana S. et al. (2002) Two novel tumor suppressor gene loci on chromosomes 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man. Oncogene 21: 5975-5980
70. Huang S., Jean D., Luca M., Tainsky M. A. and Bar-Eli M. (1998) Loss of AP-2α results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17: 4358-4369
71. Natali P. G., Nicotra M. R., Winkler A. B., Cavaliere R., Bigotti A. and Ullrich A. (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-KIT protooncogene receptor. Int. J. Cancer 52: 197-201
72. Bar-Eli M. (1999) Role of AP-2α in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 18: 377-385
73. Jean D., Gershenwald J. E., Huang S., Luca M., Hudson M. J., Tainsky M. A. et al. (1998) Loss of AP-2α results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J. Biol. Chem. 273: 16501-16508
74. Woenckhaus C., Giebel J., Failing K., Fenic I., Dittberner T. and Poetsch M. (2003) Expression of AP-2α, c-kit, cleaved caspase-6 and -3 in nevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J. Pathol., in press
75. Nyormoi O., Wang Z., Doan D., Ruiz M., McConkey D. and Bar-Eli M. (2001) Transcription factor AP-2α is preferentially cleaved by caspase 6 and degraded by proteasome dunng tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol. Cell. Biol. 21: 4856-4867
76. Ozisik Y. Y., Meloni A. M., Altungoz O., Peier A., Karakousis C., Leong S. P. L. et al. (1994) Cytogenetic findings in 21 malignant melanomas. Cancer Genet. Cytogenet. 77: 69-73
77. Pollock P. M. and Trent J. M. (2000) The genetics of cutaneous melanoma. Clin. Lab. Med. 20: 667-690.
78. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K. and Carson D. A. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
79. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V. et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
80. Spruck C. H. 3rd, Gonzalez-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F. et al. (1994) p16 gene in uncultured tumors. Nature 370: 183-184
81. Reed A. L., Califano J., Cairns P., Westra W. H., Jones R. M., Koch W. et al. (1996) High frequency of p16 (CDKN2/MTS1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56: 3630-3633
82. Mori T., Miura K., Aoki T., Nishihira T., Mori S. and Nakamura Y. (1994) Frequent somatic mutations of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54: 3396-3397
83. Maesawa C., Tamura G., Nishizuka S., Ogasawara S., Ishida K., Terashima M. et al. (1996) Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 56: 3875-3878
84. Caldas C., Hahn S. A., da Costa L. T., Redston M. S., Schutte M., Seymour A. B. et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32
85. Shapiro G. I., Edwards C. D., Kobzik L., Godleski J., Richards W., Sugarbaker D. J. et al. (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55: 505-509
86. Costello J. F., Berger M. S., Huang H. S. and Cavenee W. K. (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56: 2405-2410
87. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E. et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 4525-4530
88. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C. et al. (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686-692
89. Grana X. and Reddy E. P. (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219
90. Keller-Melchior R., Schmidt R. and Piepkorn M. (1998) Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J. Invest. Dermatol. 110: 932-938
91. Castellano M., Pollock P. M., Walters M. K., Sparrow L. E., Down L. M., Gabrielli B. G. et al. (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 57: 4868-4875
92. Healy E., Sikkink S. and Rees J. L. (1996) Infrequent mutations of p16INK4 in sporadic melanoma. J. Invest. Dermatol. 107: 318-321
93. Ohta M., Nagai H., Shimizu M., Rasio D., Berd D., Mastrangelo M. et al. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54: 5269-5272
94. Bennet D. C. and Medrano E. E. (2002) Molecular regulation of melanocyte senescence. Pigment Cell Res. 15: 242-250
95. Rizos H., Darmanian A. P., Holland E. A., Mann G. J. and Kefford R. F. (2001) Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J. Biol. Chem. 276: 41424-41434
96. Hewitt C., Lee Wu C., Evans G., Howell A., Elles R. G., Jordan R. et al. (2002) Germline mutation of ARF in a melanoma kindred. Hum. Mol. Genet. 11: 1273-1279
97. Rizos H., Puig S., Badenas C., Malvehy J., Darmanian A. P., Jimenez L. et al. (2002) A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20: 5543-5547
98. Maedlandsmo G. M., Florenes V. A., Hovig E., Oyjord T., Engebraaten O., Holm R. et al. (1996) Involvement of pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br. J. Cancer 73: 909-916
99. Platz A., Sevigny P., Norberg T., Ring P., Lagerlof B. and Ringborg U. (1996) Genes involved in cell cycle G1 checkpoint are frequently mutated in human melanoma metastases. Br. J. Cancer 74: 936-941
100. Stone S., Dayananth P., Jiang P., Weaver-Feldhaus J. M., Tavtigian S. V., Connon-Albright L. et al. (1995) Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11: 987-991
101. Wang Y. and Becker D. (1996) Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system. Oncogene 12: 1069-1075
102. Ohta M., Berd D., Shimizu M., Nagai H., Cotticelli M.-G., Mastrangelo M. et al. (1996) Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer 65: 762-767
103. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947
104. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K. A., Lin H., Ligon A. H. et al. (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362
105. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F. and Zeuthen J. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57: 3660-3663
106. Robertson G. P., Furnari F. B., Miele M. E., Glendening M. J., Welch D. R., Fountain J. W. et al. (1998) In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl. Acad. Sci. USA 95: 9418-9423
107. Tsao H., Zhang X., Benoit E. and Haluska F. G. (1998) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397-3402
108. Poetsch M., Dittberner T. and Woenckhaus C. (2001) PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet. Cytogenet. 125: 21-26
109. Birck A., Ahrenkiel V., Zeuthen J., Hou-Jensen K. and Guldberg P. (2000) Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Invest. Dermatol. 114: 277-280
110. Pollock P. M., Walker G. J., Glendening J. M., Que Noy T., Bloch N. C., Fountain J. W. et al. (2002) PTEN inactivation is rare in melanoma tumors but occurs frequently in melanoma cell lines. Melanoma Res. 12: 565-575
111. Deichmann M., Thome M., Benner A., Egner U., Hartschuh W. and Naher I. (2002) PTEN/MMAC1 expression in melanoma resection specimens. Br. J. Cancer 87: 1431-1436
112. Okami K., Li W., Riggins G., Cairns P., Goggins M., Evron E. et al. (1998) Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res. 58: 509-511
113. Albarosa R., Colombo B. M., Roz L., Magnani I., Pollo B., Cirenei N. et al. (1996) Deletion mapping of gliomas suggests the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am. J. Hum. Genet. 58: 1260-1267
114. Robertson G. P., Herbst R. A., Nagane M., Huang H. J. and Cavenee W. K. (1999) The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res. 59: 3596-3601
115. Udart M., Utikal J., Krahn G. M. and Peter R. U. (2001) Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3: 245-254
116. Halaban R. (2000) The regulation of normal melanocyte proliferation. Pigment Cell Res. 13: 4-14
117. Busca R., Abbe P., Mantoux F., Aberdam E., Peyssonnaux C., Eychene A. et al. (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19: 2900-2910
118. Davies D., Bignell G. R., Cos C., Stephens P., Edkins S., Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
119. Brose M. S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R. et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62: 6997-7000
120. Pollock P. M., Harper U. L., Hansen K. S., Yudt L. M., Stark M., Robbins C. M. et al. (2002) High frequency of BRAF mutations in nevi. Nat. Genet. 33: 19-20
121. Lang J., Boxer M. and MacKie R. (2003) Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat. 21: 327-330
122. Bastian B. C., Kashani-Sabet M., Hamm H., Godfrey T., Moore D. H., Bröcker E. B. et al. (2000) Gene amplifications characterize acral melanoma and permit the detection of occult cells in the surrounding skin. Cancer Res. 60: 1968-1973
123. Sauter E. R., Un-Cheol Y., von Stemm A., Zhu W., Litwin S., Tichansky D. S. et al. (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62: 3200-3206
124. Hibberts N. A., Simpson D. J., Bicknell J. E., Broome J. C., Hoban P. R., Clayton R. N. et al. (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5: 2133-2139
125. Toyoshima H. and Hunter T. (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74
126. Kip1, cyclin-Cdk inhibitor, links transforming growth factor-B and contact inhibition to cell cycle arrest. Genes Dev. 8: 9-22
127. Kobayashi H., Montgomery K. T., Bohlander S. K., Adra C. N., Lim B. L., Kucherlapati R. S. et al. (1994) Fluorescence in situ hybridization mapping of translocations and deletion involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 84: 3473-3482
128. Takeuchi S., Tsukasaki K., Bartram C. R., Seriu T., Zimmermann M., Schrappe M. et al. (2003) Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia. Leukemia 17: 149-154
129. Kawana Y., Ichikawa T., Suzuki H., Ueda T., Komiya A., Ichikawa Y. et al. (2002) Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 53: 60-64
130. Pietenpol J. A., Bohlander S. K., Sato Y., Papadopoulos N., Liu B., Freidman C. et al. (1995) Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55: 1206-1210
131. Ponce-Castaneda M. V., Lee M.-H., Latres E., Polyak K., Lacombe L., Montgomery K. et al. (1995) p27Kip1: chromosomal mapping to 12p12 and absence of mutations in human tumors. Cancer Res. 55: 1211-1214
132. Vance J. M., Matise T. C., Wooster R., Schutte B. C., Bruns G. A. P., van Roy N. et al. (1997) Report of the third international workshop on human chromosome 1 mapping 1997. Cytogenet. Cell Genet. 78: 153-182